<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713424</url>
  </required_header>
  <id_info>
    <org_study_id>00078213</org_study_id>
    <nct_id>NCT03713424</nct_id>
  </id_info>
  <brief_title>An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction</brief_title>
  <official_title>An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is looking into the effects of clavulanic on smoking behavior in adult&#xD;
      cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid&#xD;
      will reduce smoking over the course of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarette Smoking</measure>
    <time_frame>5 days</time_frame>
    <description>Biochemical smoking assessment (breath carbon monoxide) at each study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of change in fMRI brain response to images</measure>
    <time_frame>4 days</time_frame>
    <description>Measure the effects of Clavulanic Acid on fMRI BOLD response to images (change from baseline to end of study) while participants undergo functional magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of change in fMRI brain connectivity</measure>
    <time_frame>4 days</time_frame>
    <description>Measure the effects of Clavulanic Acid on resting-state functional connectivity (change from baseline to end of study) while participants undergo functional magnetic resonance imaging.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Clav</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-day 125 bid oral capsule administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4-day, twice-daily oral capsule administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clavulanic Acid</intervention_name>
    <description>Beta lactamase inhibitor for smoking cessation</description>
    <arm_group_label>Clav</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Entry criteria:&#xD;
&#xD;
        Inclusion Criteria all subjects:&#xD;
&#xD;
          1. Age 18-65 years&#xD;
&#xD;
          2. English fluency&#xD;
&#xD;
          3. Functional vision (with corrective lenses as needed) to complete assigned assessments&#xD;
             and tasks&#xD;
&#xD;
          4. Smoke &gt; 10 cigarettes/day for a minimum of 2 yrs. and have an expired carbon monoxide&#xD;
             (CO) concentration of â‰¥ 10 ppm (to confirm inhalation at screening and scanning)&#xD;
&#xD;
          5. If female, provide a negative urine pregnancy test.&#xD;
&#xD;
          6. Agrees to refrain from all other tobacco (i.e., dip/chew, cigars, cigarillos) and/or&#xD;
             nicotine products (i.e., e-cigs, patches, gum/lozenges, inhalers/sprays) for the&#xD;
             duration of study participation&#xD;
&#xD;
        Exclusion Criteria all subjects:&#xD;
&#xD;
          1. Sensitivity or allergy to clavulanic acid/antibiotics&#xD;
&#xD;
          2. Past head injury or primary neurological disorder associated with MRI abnormalities,&#xD;
             including dementia, MCI, brain tumors, epilepsy, Parkinson's disease, or demyelinating&#xD;
             diseases&#xD;
&#xD;
          3. Any physical or intellectual disability affecting completion of assessments&#xD;
&#xD;
          4. Any contraindication to MRI&#xD;
&#xD;
          5. Use of antidepressants medications with smoking cessation efficacy&#xD;
&#xD;
          6. Presence of an untreated illness or serious medical condition&#xD;
&#xD;
          7. Current or past psychosis&#xD;
&#xD;
          8. Electroconvulsive therapy in last 6 months&#xD;
&#xD;
          9. Positive pregnancy test (Urine pregnancy testing at screening and prior to fMRI scan)&#xD;
             or currently breast feeding or BAC greater than 0.0&#xD;
&#xD;
         10. Use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous&#xD;
             if taken with CLAV) within 14 days of study participation&#xD;
&#xD;
         11. Abnormal liver function determined by Complete Metabolic Panel - liver enzymes outside&#xD;
             normal ranges of AST (SGOT) 5-40 unites/L and ALT( SGPT) 7-56units/L&#xD;
&#xD;
         12. Abnormal renal function determined by Complete Metabolic Panel - outside normal ranges&#xD;
             of BUN 6-24 mg /dl and Creatinine level 0.6 -1.2 mg /dl male, 0.5-1.1mg /dl female&#xD;
&#xD;
         13. Any other condition or concern that in the investigator's opinion would impact&#xD;
             participant safety, compliance with study instructions, or potentially confound the&#xD;
             interpretation of the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett Froeliger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhura Athreya, MS</last_name>
    <phone>573-882-2977</phone>
    <email>athreyam@health.missouri.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brett E Froeliger, PhD</last_name>
    <phone>573-882-4785</phone>
    <email>froeligerb@health.missouri.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Froeliger, PhD</last_name>
      <phone>513-882-4785</phone>
      <email>froeligerb@health.missouri.edu</email>
    </contact>
    <contact_backup>
      <last_name>Madhura Athreya, MS</last_name>
      <phone>573-882-2977</phone>
      <email>athreyam@health.missouri.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Brett Froeliger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

